UT Southwestern | Strategic Alliance Partners

Connect with us:

Latest from UT Southwestern

Dr. McArthur on the FDA Approval of Second-Line Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 06, 2022

Video

Heather McArthur, MD, MPH, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki for second-line treatment in HER2-positive metastatic breast cancer.

ARO-HIF2 Lowers HIF2α Expression and Demonstrates Favorable Safety Profile in Clear Cell RCC

May 04, 2022

Article

The investigational RNA interference therapy, ARO-HIF2, reduced levels of hypoxia inducible factor-2 alpha expression and had acceptable tolerability when used in patients with clear cell renal cell carcinoma, according to data from the phase 1b AROHIF21001 trial.

Tucatinib Plus T-DM1 Represents Another Potential Therapy in High-Risk HER2-Positive Breast Cancer

May 03, 2022

Article

Heather McArthur, MD, MPH, discusses key treatment developments in early-stage and metastatic HER2-positive breast cancer and triple-negative breast cancer, plus ongoing research at UT Southwestern Harold C. Simmons Comprehensive Cancer Center.

State of Science Summit- Breast Cancer: Chaired by Heather McArthur, MD

April 12, 2022

Article

State of Science Summit- Breast Cancer: Chaired by Heather McArthur, MD

Experimental Drug Could Spur Immunotherapy Response in Patients With Non–Small Cell Lung Cancer

April 05, 2022

Article

Research led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non–small cell lung cancers to respond to an immune checkpoint blockade, a therapy that harnesses the immune system to fight malignant tumors.

Pacritinib Paves a “Unique Lane” of Treatment for Select Myelofibrosis

April 05, 2022

Article

Patients who develop post–essential thrombocythemia myelofibrosis or post–polycythemia vera myelofibrosis, which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effective treatment.

Dr. Mesa on the Unique Characteristics of Momelotinib in Myelofibrosis

January 26, 2022

Video

Ruben A. Mesa, MD, discusses the unique characteristics of momelotinib in myelofibrosis.

Dr. Anderson on the Methods Utilized in the KarMMa Trial in Multiple Myeloma

October 06, 2021

Video

Larry Anderson, MD, PhD, discusses the methods utilized in the phase 2 KarMMa trial in multiple myeloma.

Dr. Anderson on the Challenges Faced With CAR T-Cell Therapy in Myeloma

September 16, 2021

Video

Larry Anderson, MD, PhD, discusses the challenges faced with CAR T-cell therapy in patients with multiple myeloma.

Dr. Singal on the Results of a Mailed Outreach Strategy for Surveillance Utilization in HCC

September 04, 2021

Video

Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.

Dr. Rich on the Prevalence of Cachexia in HCC

September 04, 2021

Video

Nicole Rich, MD, discusses the prevalence of cachexia in hepatocellular carcinoma.

Dr. Hammers on the Safety Profile of Lenvatinib/Pembrolizumab in RCC

August 20, 2021

Video

Hans Hammers, MD, PhD,discusses the safety profile of lenvatinib in combination with pembrolizumab in renal cell carcinoma.

Neoadjuvant Stereotactic Radiation Shows Early Safety, Feasibility in RCC Inferior Vena Cava Tumor Thrombus

August 12, 2021

Article

Neoadjuvant stereotactic radiation followed by radical nephrectomy and thrombectomy is a safe and feasible treatment option for patients with renal cell carcinoma and inferior vena cava tumor thrombus.

Dr. Hammers on the Potential Utility of HIF-2α Inhibitors in RCC

June 02, 2021

Video

Hans Hammers, MD, PhD, discusses the potential utility of HIF-2α inhibitors in renal cell carcinoma.

Dr. Hammers on the Importance of Assessing Quality of Life in RCC

May 12, 2021

Video

Hans Hammers, MD, PhD, discusses the importance of assessing quality of life in renal cell carcinoma.

Dr. Jones on Future Research Efforts in Pancreatic Cancer

May 03, 2021

Video

Amy Jones, MD, discusses future research efforts in pancreatic cancer.

Dr. Kazmi on Key Treatment Considerations for Young-Onset CRC

May 03, 2021

Video

Syed Kazmi, MD, an oncologist at The University of Texas Southwestern Medical Center, discusses key treatment considerations for young patients with onset colorectal cancer.

Tailoring Targeted Therapies in Metastatic CRC

April 13, 2021

Article

Syed Kazmi, MD, highlights the go-to regimens for patients with mCRC.

Dr. Kazmi on Tailoring Treatment to Various Subtypes of CRC

March 19, 2021

Video

Syed Kazmi, MD, discusses the importance of tailoring treatment to different subtypes of colorectal cancer.

Dr. Jones on Selecting Between Frontline Regimens in Pancreatic Cancer

March 05, 2021

Video

Amy Jones, MD, discusses factors that can inform frontline treatment selection in pancreatic cancer.